Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) was the target of a large drop in short interest in August. As of August 14th, there was short interest totaling 26,210 shares, a drop of 44.9% from the July 30th total of 47,525 shares. Based on an average daily trading volume, of 49,980 shares, the short-interest ratio is presently 0.5 days. Currently, 0.0% of the company’s stock are sold short.
Anbio Biotechnology Stock Performance
Shares of NNNN traded down $0.52 during midday trading on Monday, hitting $7.15. 268,379 shares of the company’s stock traded hands, compared to its average volume of 60,956. Anbio Biotechnology has a 1 year low of $6.61 and a 1 year high of $51.33. The firm’s fifty day moving average is $10.51 and its 200-day moving average is $20.02.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
See Also
- Five stocks we like better than Anbio Biotechnology
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
